These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7622847)

  • 21. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Treating hypertension" or "lowering blood pressure"? Extending the concept.
    Chalmers J
    Blood Press; 2002; 11(2):68-70. PubMed ID: 12035873
    [No Abstract]   [Full Text] [Related]  

  • 23. [The basic treatment of arterial hypertension (II). Pharmacological treatment].
    Pascual J; Orte L; Ortuño J
    Med Clin (Barc); 1994 Nov; 103(18):699-707. PubMed ID: 7808078
    [No Abstract]   [Full Text] [Related]  

  • 24. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. Italian Nifedipine GITS Study Group.
    Zanchetti A
    J Hypertens Suppl; 1994 Nov; 12(8):S97-106. PubMed ID: 7707165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for treating hypertension.
    Kawachi I; Purdie G
    N Z Med J; 1990 Jan; 103(882):22-4. PubMed ID: 2304678
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical implications of trough to peak ratio].
    Hasebe N; Kikuchi K
    Nihon Rinsho; 2000 Feb; 58 Suppl 2():224-7. PubMed ID: 11028328
    [No Abstract]   [Full Text] [Related]  

  • 28. Trough/peak ratios for antihypertensive agents. The issues in perspective.
    Meredith PA
    Drugs; 1994 Nov; 48(5):662-6. PubMed ID: 7530624
    [No Abstract]   [Full Text] [Related]  

  • 29. Trough to peak ratio: time for reappraisal?
    Millar JA
    J Hum Hypertens; 1998 Jan; 12(1):35-6. PubMed ID: 9482131
    [No Abstract]   [Full Text] [Related]  

  • 30. Trough to peak ratio: current status and applicability.
    Elliott HL
    J Hum Hypertens; 1998 Jan; 12(1):55-9. PubMed ID: 9482135
    [No Abstract]   [Full Text] [Related]  

  • 31. Blood pressure control and the implementation of guidelines in clinical practice: can we fill the gap?
    Burnier M;
    J Hypertens; 2002 Jul; 20(7):1251-3. PubMed ID: 12131512
    [No Abstract]   [Full Text] [Related]  

  • 32. Trough-to-peak ratios: some statistical considerations.
    Stewart WH
    Am J Hypertens; 1996 Oct; 9(10 Pt 2):83S-86S; discussion 87S-90S. PubMed ID: 8896669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trough: peak ratio: measurement, limitations and relevance to treatment of hypertension. Workshop proceedings. Vienna, Austria, 4 February 1994.
    J Hypertens Suppl; 1994 Nov; 12(8):S1-119. PubMed ID: 7707148
    [No Abstract]   [Full Text] [Related]  

  • 34. [Blood pressure treatment is irrelevant immediately after ischemic stroke].
    Markun S
    Praxis (Bern 1994); 2014 Feb; 103(5):291-2. PubMed ID: 24568767
    [No Abstract]   [Full Text] [Related]  

  • 35. From the Editor.
    Levy D
    J Am Soc Hypertens; 2017 May; 11(5):245. PubMed ID: 28595739
    [No Abstract]   [Full Text] [Related]  

  • 36. Secondary hypertension--whom and how do you study? What type of therapy is appropriate?
    Moser M; Victor R; Handler J
    J Clin Hypertens (Greenwich); 2005 Apr; 7(4):224-30. PubMed ID: 15860962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertension and chronic kidney disease progression: why the suboptimal outcomes?
    Bidani AK; Griffin KA; Epstein M
    Am J Med; 2012 Nov; 125(11):1057-62. PubMed ID: 22906957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
    Sharma AM; Davidson J; Koval S; Lacourcière Y
    Cardiovasc Diabetol; 2007 Oct; 6():28. PubMed ID: 17910747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of sustained release formulations in the treatment of hypertension. An overview.
    Mutschler E; Knauf H
    Clin Pharmacokinet; 1999; 37 Suppl 1():1-6. PubMed ID: 10491727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trough: peak ratio: clinically useful or practically irrelevant?
    Elliott HL; Meredith PA
    J Hypertens; 1995 Mar; 13(3):279-83. PubMed ID: 7622847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.